16,16-Dimethylprostaglandin E2 (16,16 Dimethylprostaglandin E2)

A synthetic prostaglandin E analog that protects the gastric mucosa, prevents ulceration, and promotes the healing of peptic ulcers. The protective effect is independent of acid inhibition. It is also a potent inhibitor of pancreatic function and growth of experimental tumors.

Also Known As:

Networked: 22 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ma, Weiya: 1 article (11/2014)
2.	St-Jacques, Bruno: 1 article (11/2014)
3.	Gretzera, B: 1 article (11/2001)
4.	Maricic, N: 1 article (11/2001)
5.	Peskar, B M: 1 article (11/2001)
6.	Schmassmann, A: 1 article (11/2001)
7.	Schuligoi, R: 1 article (11/2001)

Related Diseases

1.	Body Weight (Weight, Body) 07/01/1995 - "The higher dose of 16,16-dimethyl-PGE2 (200 micrograms/kg body weight) caused a significant reduction in both PFC number and antibody titre compared with the control. " 07/01/1989 - "Administration of either tumour necrosis factor alpha (TNF-alpha) or 16,16-dimethylprostaglandin E2 (PGE2) to female NMRI mice caused a decrease in body weight accompanied by a reduction in both food and water intake and a decrease in carcass water content. "
2.	Cholangitis 07/01/1984 - "16,16-dimethyl-PGE2 protection against alpha-naphthylisothiocyanate-induced experimental cholangitis in the rat."
3.	Stomach Ulcer (Gastric Ulcer) 01/01/1991 - "This study was designed to test the beneficial effects of 16,16-dimethylprostaglandin E2 or TRY-200, a stable prostaglandin I2 analogue, on the delayed healing by hydrocortisone (HC) of chronic gastric ulcers in rats. "
4.	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 02/01/1981 - "We examined the effects of 16,16 dimethylprostaglandin E2 (DMPGE2) on the development of diabetic ketoacidosis (DKA) in rats. " 02/01/1981 - "Enhancement of ketosis by 16,16 dimethylprostaglandin E2 during the genesis of diabetic ketoacidosis in rats." 10/01/1979 - "Persistence of ketosis despite suppression of lipolysis by 16,16-dimethylprostaglandin E2 in experimental diabetic ketoacidosis in rats."
5.	Neoplasms (Cancer) 08/01/1987 - "An intraperitoneal dose of 16,16-dimethyl-PGE2 (5 micrograms/mouse, daily) reduced the anti-tumor activity of indomethacin. " 12/01/1988 - "The in vitro and in vivo effects of prostaglandin E2 (PGE2) and of its stable analogue, 16,16-dimethyl-PGE2 (dmPGE2), on myelopoiesis and on the myelopoiesis-associated immune suppressor cell activity of mice bearing metastatic variant Lewis lung carcinoma (LLC-C3) tumors are assessed. "

Related Drugs and Biologics

1.	1-Naphthylisothiocyanate (1 Naphthylisothiocyanate)
2.	Epoprostenol (Prostacyclin)
3.	Hydrocortisone (Cortisol)
4.	TRY 200
5.	Dinoprostone (PGE2)
6.	Esters
7.	Prostaglandins
8.	Morphine (MS Contin)
9.	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
10.	N-Acetylneuraminic Acid (Sialic Acid)

Related Therapies and Procedures

1.	Intravenous Infusions